Premium
GABOB (γ‐AMINO‐β‐HYDROXYBUTYRIC ACID) TREATMENT IN EPILEPSY
Author(s) -
Wada Toyoji,
Goto Akira,
Fukushima Yutaka,
Tateyama Koh
Publication year - 1961
Publication title -
psychiatry and clinical neurosciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.609
H-Index - 74
eISSN - 1440-1819
pISSN - 1323-1316
DOI - 10.1111/j.1440-1819.1961.tb00659.x
Subject(s) - epilepsy , anesthesia , medicine , antiepileptic drug , pharmacology , psychiatry
Summary The authors studied the effect of GABOB on 150 epileptics with various types of seizures. The study was carried out in 2 groups, the old cases and the new ones. The former were made up of patients who had been given an ordinary antiepileptic medication for periods of time, and then GABOB was added later on. The latter group patients were given only GABOB from the beginning. 1) In 99 old cases with the total 116 seizures, the effect of medication prior to GABOB was increased for 22 %, unchanged for 48 % and reduced for 30 %. And, of the 25 old cases with the total 37 seizures, given GABOB and the dose of previous medication reduced, the rate of influence was %, 45 % and 41 %. Therefore, a synergistic effect between GABOB and the other antiepileptic drugs seemed to be little. 2) GABOB represented prominent effects in 26 new cases with 28 seizures: 50^ were completely controlled and 25 % showed certain improvements. 3) It is most effective for seizure of convulsive type and for children. 4) The optimal dose of GABOB was estimated as 1.0–1.5 g. daily for adults and as 0.5‐1.0g. for children, but the effect cannot be ascertained immediately. No marked side effects were noticed, however, the effect of GABOB showed a great individual variation. 5) The authors feel that GABOB may serve as a guide for introduction of new antiepileptic drugs.